Clinical Trials Directory

Trials / Completed

CompletedNCT05553067

Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms

Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms.

Status
Completed
Phase
Study type
Observational
Enrollment
100 (actual)
Sponsor
Sohag University · Academic / Other
Sex
Female
Age
20 Years – 70 Years
Healthy volunteers

Summary

Detection of the potential oncogenic role of Engrailed-2 in epithelial ovarian neoplasms, in order to detect biological markers that could be targeted and blocked by new medications.

Detailed description

Epithelial ovarian carcinomas represent more than 90% of all ovarian carcinomas. Treatment of these ovarian carcinomas on basis of their histopathological features didn't improve patients' outcomes with very high incidence of relapses and resistance to therapy. Detection of novel biological markers which are involved in tumor progression could have promising results if these biological molecules are targeted and blocked by new medications. Engrailed-2 is a protein encoded by a gene located on chromosome 7. Engrailed-2 is involved in neural development and neural connections during embryological life. it has been proved that Engrailed-2 is expressed in non neural neoplasms, especially in prostatic and urinary bladder carcinomas. Now estimatiion of urinary and serum levels of Engrailed-2 is used as a non-invasive screening tool in to detect prostatic and urinary bladder carcinomas. We aim to evaluated immunohistochemical expression of Engrailed-2 in normal and neoplastic ovarian tissues and to compare such expression between normal and neoplastic tissues in order to improve its oncogenic role in ovarian carcinoma.

Conditions

Interventions

TypeNameDescription
GENETICImmunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody.Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody and compare levels of expression in different ovarian specimens to detect its potential role in oncogenesis of ovarian carcinoma.

Timeline

Start date
2015-01-01
Primary completion
2021-12-31
Completion
2022-06-01
First posted
2022-09-23
Last updated
2022-09-27

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05553067. Inclusion in this directory is not an endorsement.